Inactive Instrument

Rekah Pharmaceutical Industry Ltd. Share Price TEL AVIV STOCK EXCHANGE

Equities

REKA

IL0010810096

Pharmaceuticals

Financials

Sales 2022 292M 76.8M 6.14B Sales 2023 322M 84.49M 6.76B Capitalization 169M 44.32M 3.54B
Net income 2022 -2M -525K -42M Net income 2023 -6M -1.58M -126M EV / Sales 2022 1.1 x
Net Debt 2022 145M 38.2M 3.05B Net Debt 2023 166M 43.72M 3.5B EV / Sales 2023 1.04 x
P/E ratio 2022
-85.5 x
P/E ratio 2023
-24.2 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 17.36%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 80 23/08/93
Director of Finance/CFO 44 31/10/18
Director/Board Member 78 23/08/93
Members of the board TitleAgeSince
Director/Board Member 62 14/04/15
Director/Board Member 52 14/04/15
Chairman 77 14/04/15
More insiders
Rekah Pharmaceutical Industry Ltd. (Rekah) is an Israel-based company which operates directly and through its subsidiaries. The Company operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The Company distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
More about the company